A preliminary investigation of phoshodiesterase 7 inhibitor VP3.15 as therapeutic agent for the treatment of experimental autoimmune encephalomyelitis mice
Marı́a Isabel Martı́n(Biomedical Research Networking Center on Neurodegenerative Diseases), Guadalupe Mengod(Consejo Superior de Investigaciones Científicas), Ana Martı́nez(Consejo Superior de Investigaciones Científicas), Carmen Gil(Instituto de Salud Carlos III), Nuria Paúl-Fernández(Biomedical Research Networking Center on Neurodegenerative Diseases)
Cited by 30
Related Papers
Distribution and cellular localization of mRNA coding for 5-HT1A receptor in the rat brain: correlation with receptor binding
|Journal of Neuroscience|1992|689
COVID-19: Drug Targets and Potential Treatments
|Journal of Medicinal Chemistry|2020|469
First Non-ATP Competitive Glycogen Synthase Kinase 3 β (GSK-3β) Inhibitors: Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer's Disease
|Journal of Medicinal Chemistry|2002|448
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS
|Frontiers in Molecular Neuroscience|2011|348
Glycogen synthase kinase 3 (GSK‐3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation
|Medicinal Research Reviews|2002|334